Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Zhang, Ping ^a,b   Zhang, Zhiyuan ^a,b   Zhou, Xiaojian ^a,b   Qiu, Weiliu ^a,b   Chen, Fangan ^c   Chen, Wantao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Key Laboratory of Stomatology   (China)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; CCND1 PROTEIN; CCND3 PROTEIN; CELL CYCLE PROTEIN; CISPLATIN; DNA; GLUTATHIONE TRANSFERASE P1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HELICASE; MAP2K6 PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN DERIVATIVE; RECQL PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; CULTURE MEDIUM; DNA REPAIR; DOWN REGULATION; DRUG EXPOSURE; DRUG SENSITIVITY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MICROARRAY ANALYSIS; MOUTH CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR DIFFERENTIATION; UPREGULATION; VALIDATION STUDY; WESTERN BLOTTING;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; PHENOTYPE; TIME FACTORS;

EID: 33749402088     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-224     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1999. CA Cancer J Clin 1999, 49:8-31.
2. Pignon JP, Bourhis J, Domenge CD, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355:949-955.
3. Plooy AC, Van Dijk M, Lohman PH: Induction and repair of DNA-cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, murtagenicity, and antitumor activity. Cancer Res 1984, 44:2043-2051.
4. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo, BC, Kim HK, Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004, 10:272-284.
5. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D: Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003, 22:663-670.
6. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, Kikuchi Y, Tenjin Y: Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001, 14:305-315.
7. Bello VE, Aloyz RS, Christodoulopoulos G, Panasci L: Homologous recombinational repair is-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002, 63:585-1588.
8. Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, Defazio A: MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology 2006, 100:239-246.
9. Kuriakose MA, Chen WT, He ZM, Sikora AG, Zhang P, Zhang ZY, Qiu WL, Hsu DF, Mcmunn-Coffran C, Brown SM, Elango EM, Delacure MD, Chen FA: Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci 2004, 61:1372-1383.
10. Huang D, Chen W, He R, Yu F, Zhang Z, Qiu W: Different cDNA microarray patterns of gene expression reflecting changes during metastatic progression in adenoid cystic carcinoma. World J Surg Oncol 2003, 1:28 [http://www.wiso.com/content/1/1/28].
11. Zhang P, Chen WT, Zhou XJ, Qiu WL: Prediction value of cyclinDs in cisplatin sensitivity of oral and maxillofacial squamouse cell carcinoma. J OMS 2005, 15:128-31.
12. Chen WT, Zhou XJ, Xu Q, Guo W, Lin LS: Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens. Zhonghua Kou Qiang Yi Xue Za Zhi 2002, 37:404-407.
13. Plumb JA, Milroy R, Kaye SB: Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989, 49:4435-4440.
14. Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, Fujita S: Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep 2005, 13:709-714.
15. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, The BT: Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004, 10:8204-8213.
16. Higuchi E, Oridate N, Furuta Y, Suzuki S, Hatakeyama H, Sawa H, Sunayashiki-Kusuzaki K, Yamazaki K, Inuyama Y, Fukuda S: Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray. Head Neck 2003, 25:187-193.
17. Funato T, Satou J, Kozawa K, Fujimaki S, Miura T, Kaku M: Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep 2001, 8:807-810.
18. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 47:7265-7279.
19. Kartner N, Shales M, Riordan JR, Ling V: Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 1983, 43:4413-4419.
20. Taniguchi K, Wada M, Kohno, K, Nakamura Y, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996, 56:4124-4129.
21. Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R: Involvement of GI/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 2002, 21:8158-8165.
22. Tran HM, Shi G, Li G, Carney JP, O'Malley B; Li D: Mutant NbsI enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg 2004, 131:477-484.
23. Sheibani N, Jennerwein MM, Eastman A: DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 1989, 28:3120-3124.
24. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR: Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine latinum (IV) dicarboxylates. Cancer Res 1992, 52:3857-3864.
25. Chao CC, Lee YL, Cheng PW, Lin-Chao S: Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). Cancer Res 1991, 51:601-605.
26. Siddik ZH, Mims B, Lozano G, Thai G: Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin -resistant ovarian tumor cell line. Cancer Res 1998, 58:698-703.
27. Lee SI, Brown MK, Eastman A: Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem pharmacol 1999, 58:1713-1721.
28. Kozubik A, Horvath V, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Zak F, Mistr A, Turanek J: High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem Pharmacol 2005, 69:373-383.
29. 1-phase progression. Genes Dev 1999, 13:1501-1512.
30. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A: Cloning and characterization of human CCND3, a cDNA closely related in sequence to the PRAD1/CCND1 proto-oncogene. J Biol Chem 1992, 267:20412-20420.
31. Zhang L, Plon SE, Nuchtern JG, Burlingame S, Blaney S, Rousseau R, Berg S: Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer drugs 2004, 15:883-888.
32. Wang MB, Yip HT, Srivatsan ES: Antisense cyclin DI enhances sensitivity of head and neck cancer cells to displatin. Laryngoscope 2001, 111:982-988.